Le document pr\u00e9sente Filsuvez, un m\u00e9dicament destin\u00e9 au traitement de l\u2019\u00e9pidermolyse bulleuse (EB) chez l\u2019adulte et l\u2019enfant \u00e0 partir de 6 mois. L\u2019EB est d\u00e9crite comme une maladie h\u00e9r\u00e9ditaire rare de la peau, provoquant une grande fragilit\u00e9 cutan\u00e9e, des cloques et des cicatrices s\u00e9v\u00e8res. Filsuvez est indiqu\u00e9 pour deux formes d\u2019EB, l\u2019EB dystrophique et l\u2019EB jonctionnelle, pour le traitement des plaies cutan\u00e9es de profondeur partielle (atteinte des couches superficielles de la peau). En raison de la raret\u00e9 de la maladie, Filsuvez b\u00e9n\u00e9ficie du statut de \u00ab m\u00e9dicament orphelin \u00bb depuis le 23 f\u00e9vrier 2011, dans le cadre du dispositif europ\u00e9en de m\u00e9dicaments pour maladies rares, sous la responsabilit\u00e9 de l\u2019Agence europ\u00e9enne des m\u00e9dicaments (EMA).<\/p>\n
Filsuvez se pr\u00e9sente sous forme de gel contenant un extrait sec d\u2019\u00e9corce de bouleau, riche en triterp\u00e8nes (notamment b\u00e9tuline, acide b\u00e9tulinique, \u00e9rythrodiol, lup\u00e9ol, acide ol\u00e9anolique). Le gel est appliqu\u00e9 en couche d\u2019environ 1 mm sur la plaie, puis recouvert d\u2019un pansement, ou directement sur le pansement, et renouvel\u00e9 \u00e0 chaque changement de pansement jusqu\u2019\u00e0 cicatrisation. Le m\u00e9dicament est disponible uniquement sur prescription m\u00e9dicale. En cas d\u2019absence d\u2019am\u00e9lioration ou de complications de plaie, un professionnel de sant\u00e9 doit r\u00e9\u00e9valuer la poursuite du traitement. Le m\u00e9canisme d\u2019action exact n\u2019est pas enti\u00e8rement \u00e9lucid\u00e9, mais l\u2019extrait d\u2019\u00e9corce de bouleau pourrait favoriser la prolif\u00e9ration et la migration des k\u00e9ratinocytes vers la zone l\u00e9s\u00e9e, contribuant ainsi \u00e0 la cicatrisation.<\/p>\n
L\u2019efficacit\u00e9 de Filsuvez a \u00e9t\u00e9 \u00e9valu\u00e9e dans une \u00e9tude principale incluant 223 adultes et enfants atteints d\u2019EB dystrophique ou jonctionnelle et pr\u00e9sentant des plaies de profondeur partielle. Parmi les patients trait\u00e9s par Filsuvez associ\u00e9 \u00e0 un pansement, 41 % ont pr\u00e9sent\u00e9 une fermeture compl\u00e8te de la plaie en 45 jours, contre 29 % dans le groupe recevant un gel t\u00e9moin (placebo) avec pansement. Aucune diff\u00e9rence n\u2019a \u00e9t\u00e9 observ\u00e9e entre Filsuvez et le gel t\u00e9moin au-del\u00e0 de 90 jours. Les effets ind\u00e9sirables les plus fr\u00e9quents (plus d\u20191 patient sur 10) sont des complications de plaies. D\u2019autres effets ind\u00e9sirables courants (plus d\u20191 patient sur 100) incluent des r\u00e9actions cutan\u00e9es au site d\u2019application, des infections de plaies, un prurit et des r\u00e9actions d\u2019hypersensibilit\u00e9. La liste compl\u00e8te des effets ind\u00e9sirables figure dans la notice.<\/p>\n
Les autorit\u00e9s europ\u00e9ennes consid\u00e8rent que Filsuvez apporte un b\u00e9n\u00e9fice d\u00e9montr\u00e9 pour les patients atteints d\u2019EB dystrophique ou jonctionnelle, dans un contexte de plaies difficiles \u00e0 cicatriser, douloureuses et \u00e0 risque infectieux, et o\u00f9 les options th\u00e9rapeutiques sont limit\u00e9es. Les effets sont qualifi\u00e9s de modestes mais cliniquement significatifs, ce qui peut pr\u00e9senter un int\u00e9r\u00eat pour le suivi des politiques de prise en charge des maladies rares, de la cicatrisation des plaies chroniques et des dispositifs de m\u00e9dicaments orphelins au niveau europ\u00e9en. (contenu r\u00e9sum\u00e9 en fran\u00e7ais par l’IA)\u00a0\u200bLire la Suite<\/a><\/p>","protected":false},"excerpt":{"rendered":" Le document pr\u00e9sente Filsuvez, un m\u00e9dicament destin\u00e9 au traitement de l\u2019\u00e9pidermolyse bulleuse (EB) chez l\u2019adulte et l\u2019enfant \u00e0 partir de 6 mois. L\u2019EB est d\u00e9crite comme une maladie h\u00e9r\u00e9ditaire rare […]<\/p>\n","protected":false},"author":1,"featured_media":17698,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[7],"tags":[257,227,226],"class_list":["post-20003","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicaments-et-produits-de-sante","tag-ema","tag-ia","tag-sources-etrangeres"],"_links":{"self":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts\/20003","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20003"}],"version-history":[{"count":0,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts\/20003\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/media\/17698"}],"wp:attachment":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20003"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20003"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20003"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}